Adalimumab Biosimilar Tracking

GRx + Biosims 2024

Prepared for: BIOSIMILARS COUNCIL™ A DIVISION OF AAM

While adalimumab biosimilar share grew 4x following the launch of co-branded formulations, uptake still trails typical biosimilar and generic uptake



*Biologic LoE average includes rituximab, bevacizumab, trastuzumab, epoetin alfa, pegfilgrastim, and infliximab
Source: IQVIA NSP, US Market Access Strategy Consulting and Thought Leadership analysis

Biosimilar monthly fill volume grew 400% from March to April 2024, with co-branded Hyrimoz driving the April spike as Caremark shifted its formulary

Despite growing claim counts, Humira volume still dwarfs biosimilar writing by a factor of 3 to 1



*Data through August 2024, projected to account for September
Source: IQVIA LAAD 3.0 , US Market Access Strategy Consulting analysis

Despite recent wins, biosimilars still make up less than 20% of total adalimumab volume across channels

Overall adalimumab volume has declined due to new branded market entrants



*Data through August 2024, projected to account for September
Source: IQVIA LAAD 3.0 , US Market Access Strategy Consulting analysis

Looking back to 2021, the total drop in adalimumab volume can be attributed to the growth in Rinvoq and Skyrizi utilization

These products have successfully taken share from Humira to mitigate the impact of LOE



*Data through August 2024, projected to account for September
Source: IQVIA LAAD 3.0 , US Market Access Strategy Consulting analysis

IQVIA

Adalimumab biosimilar approval rates are substantially higher outside of the “Big 3” PBMs

Hyrimoz is the only biosimilar with favorable access from large payers in the time period analyzed



Source: US Market Access Strategy Consulting analysis; IQVIA LAAD 3.0

Despite Hyrimoz's recent successes, most adalimumab-naïve patients are treated with Humira

58% of new-to-class patients are treated with Humira, while 62% of switch patients receive Hyrimoz



Other treatments include Stelara, Entyvio, Enbrel, Remicade, infliximab biosimilars, Orencia, Simponi, Otezla, Tremfya, Cosentyx, Taltz, Sotyktu, and Zeposia among others
Source: US Market Access Strategy Consulting analysis; IQVIA LAAD 3.0

Humira Biosimilar Adoption: Hints of Progress or Signs of Doom?

1 Adalimumab uptake **trails other biosimilar** and generic launches

2 The total **adalimumab market has shrunk** as patients move to Skyrizi and Rinvoq

3 Despite some recent formulary wins, large payers are **generally restricting access** to biosimilars and covering Humira

Adalimumab LoE vs Other LoE Events
TRx Share, Indexed to Launch



Adalimumab TRx Market Share
Q4-2022 through Q3-2024



Adalimumab Utilization Management
"Big 3" PBMs, Jan 2024 – August 2024



Source: US Market Access Strategy Consulting analysis; IQVIA LAAD 3.0

For more information, please contact
Nick Adolph (Nick.Adolph@IQVIA.com)